2-TOIFA DIABETNING FENOTIPIK STRATIFIKATSIYASI: SHAXSIYLASHTIRILGAN TIBBIYOTNING YANGI UFQLARI
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrak:
2-tur qandli diabet (QD2) 21-asrning jiddiy tibbiy va ijtimoiy muammosi bo'lib, butun dunyo bo'ylab 500 milliondan ortiq odam kasallangan. 2-tur diabet bitta kasallik deb hisoblansada, aslida u turli xil klinik ko'rinishlarga, metabolik xususiyatlarga, asoratlar xavfiga va davolanishga javob beradigan geterogen guruhdir. Zamonaviy endokrinologiya "insulinrezistentligi + giperglikemiya" ning soddalashtirilgan modelidan voz kechadi va kasallikni keltirib chiqaradigan patofiziologik mexanizmlarning xilma-xilligini aks ettiruvchi QD2 fenotiplari kontseptsiyasiga o'tadi. Ushbu umumiy tashxis odatda bir nechta toifalarga bo'linadi, jumladan 1-tur diabet, 2-tur diabet, gestatsion qandli diabet va boshqa sabablarga ko'ra (masalan, dori-darmonlar) kelib chiqqan diabet, diabetning ko'p holatlari 2-tur (90-95%) yoki 1-tur (5-10%) deb tasniflanadi.
##plugins.themes.bootstrap3.article.details##
##submission.howToCite##:
##submission.citations##:
American Diabetes Association Professional Practice Committee (2022) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 45(Suppl 1): S17–S38. https://doi.org/10.2337/dc22-S002
Bravis V, Kaur A, Walkey HC et al (2018) Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open 8(4):e020904. https://doi.org/10.1136/bmjopen-2017-020904
Cefalu WT, Andersen DK, Arreaza-Rubín G et al (2022) Heterogeneity of Diabetes: B-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research’s Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Care 45(1):3–22
Stidsen JV, Henriksen JE, Olsen MH et al (2018) Pathophysiologybased phenotyping in type 2 diabetes: A clinical classification tool. Diabetes Metab Res Rev 34(5):e3005. https://doi.org/10.1002/ dmrr.3005
Li L, Cheng W-Y, Glicksberg BS et al (2015) Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci Transl Med 7(311):311ra174. https://doi.org/10.1126/ scitranslmed.aaa9364
Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a datadriven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369. https://doi.org/10.1016/S2213-8587(18) 30051-2
Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7(9):684–694. https://doi.org/10.1016/S2213-8587(19)30187-1
Slieker RC, Donnelly LA, Fitipaldi H et al (2021) Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia 64(9):19821989. https://doi.org/10.1007/s00125-021-05490-8
Anjana RM, Baskar V, Nair ATN et al (2020) Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Res Care 8(1):e001506. https://doi.org/10.1136/bmjdrc-2020-001506
Wu, H.; Yang, A.; Lau, E.S.H.; Zhang, X.; Fan, B.; Ma, R.C.W.; Kong, A.P.S.; Chow, E.; So, W.-Y.; Chan, J.C.N.; et al. 1-Year Weight Change after Diabetes Diagnosis and Long-Term Incidence and Sustainability of Remission of Type 2 Diabetes in Real-World Settings in Hong Kong: An Observational Cohort Study. PLoS Med. 2024, 21, e1004327.
Szendroedi J, Saxena A, Weber KS et al (2016) Cohort profile: the German Diabetes Study (GDS). Cardiovasc Diabetol 15(1):59–72. https://doi.org/10.1186/s12933-016-0374-9
Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7(6):442–451. https://doi.org/10. 1016/S2213-8587(19)30087-7
Pigeyre M, Hess S, Gomez MF et al (2022) Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia 65(1):206–215. https://doi.org/10. 1007/s00125-021-05567-4
Wagner R, Heni M, Tabák AG et al (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 27(1):49–57. https://doi.org/10.1038/s41591-020-1116-9
Misra, S.; Wagner, R.; Ozkan, B.; Schön, M.; Sevilla-Gonzalez, M.; Prystupa, K.; Wang, C.C.; Kreienkamp, R.J.; Cromer, S.J.; Rooney, M.R.; et al. Precision Subclassification of Type 2 Diabetes: A Systematic Review. Commun. Med. 2023, 3, 138.
Cariou, B.; Byrne, C.D.; Loomba, R.; Sanyal, A.J. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes. Metab. 2021, 23, 1069–1083.
Wang, Y.; Fleishman, J.S.; Li, T.; Li, Y.; Ren, Z.; Chen, J.; Ding, M. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Front. Pharmacol. 2023, 14, 1336216.
Caussy, C.; Aubin, A.; Loomba, R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr. Diab. Rep. 2021, 21, 15.